Advertisement
Supported by
A team of Russian scientists published the first report on their debatable Covid-19 vaccine, locating a modest amount of antibodies in the evaluated volunteers.
now
Germany plans to shorten its quarantine era to five days out of 14.
On Friday, a team of Russian scientists published the first report on their debatable Covid-19 vaccine, which he wrote in The Lancet, reported that volunteers produced a small amount of antibodies opposed to coronavirus.
In August, President Vladimir V.Putin announced with wonderful fanfare that the vaccine, called Sputnik V, “works well enough” to be approved.He said it was a “very vital step for our country and for the world at large.”
But the vaccine’s developers strongly criticized the ad, noting that no knowledge of the vaccine had been disclosed.In addition, Russian scientists had not yet conducted a large-scale trial to show that the vaccine was effective.
The new article is the first to take a closer look at the Sputnik V.
Researchers from the Gamaleya Research Institute designed the vaccine, another virus as a vehicle to transmit coronavirus genes to cells.Vehicle viruses, called adenoviruses, have been disabled so that they can only enter cells, but not replicate.
Adenoviruses carried a coronavirus gene that encoded a protein in the virus.Cells produce protein, which then stimulates people’s immune systems.
Similar adenovirus vaccines are also being tested across several teams, adding AstraZeneca, CanSinoBio and Johnson.
The Russian team has released the effects of what is called a 1/2 test phase.This is an early level of clinical research, in which scientists give a vaccine to volunteers, see if they produce antibodies opposed to a virus and side effects.
The trial was small. Only 40 volunteers won the full vaccine with any of the types of adenovirus and no one won the placebo for comparison.By comparison, CanSinoBio conducted a Pha 1/2 2 trial that included another 383 people who won the vaccine and another 129 who won a placebo.
The Russian vaccine has produced mild symptoms in several subjects, the maximum being not unusual fever and headaches.Other adenovirus-based vaccines have produced side effects. Researchers found that volunteers who won the entire vaccine produced antibodies opposed to coronavirus.it also produced immune cells capable of responding strongly to coronavirus.
In their paper, the researchers found that the vaccine produces as many antibodies as the AstraZeneca vaccine or the gene-based vaccine manufactured through Moderna.
Akiko Iaki, an immunologist at Yale University who was not involved in the study, said the vaccine produced “good degrees of antibodies in all volunteers.”But he added that no one yet knows what point of antibodies or immune cells are needed to stay in other people.”It’s hard to know if the vaccine will be effective,” he says.
This is true for all Covid-19 vaccines that are being tested lately.Determining that a vaccine is effective requires a so-called Phase 3 trial, in which a large number of volunteers get a vaccine or placebo.who had received approval on August 26 to conduct a phase 3 trial on 40,000 people.
Moncef Slaoui, the White House’s leading adviser on the vaccination program, said Thursday that it is “extremely unlikely but not impossible” for a vaccine to be available until the end of October.
In an interview with national public radio, Dr. Slaoui said that the recommendation of the Centers for Disease Control and Prevention in states to prepare for a vaccine at the end of October “is the right thing to do” in case a vaccine “It would be irresponsible not to be prepared if that were the case,” he said, adding that he had only learned of the media notification.
But Dr. Slaoui, the leading clinical adviser to the Trump administration’s coronavirus remedy and vaccine initiative, called Operation Warp Speed, described receiving a vaccine last October as a “very, very low probability.”
The message contradicted the White House’s positive claims that a vaccine could be in a position to be distributed before Election Day in November.President Trump, at the Republican National Convention, said a vaccine could be in a position “before the end of the year.or maybe even before.”
Dr. Slaoui demonstrated that the two main candidates, called vaccine A and C.D.C.The vaccine was being developed through Pfizer and Moderna.He said there is “no intention” to introduce a vaccine before clinical trials are completed.The trials will not be completed until an indefinite protection oversight committee demonstrates the effectiveness of the vaccine, he added.
NPR interviewer Mary Louise Kelly spoke about the timing of a vaccine imaginable in DC documents recently sent to public fitness officials and asked if their functionality was politically motivated.
“For us, there’s probably nothing to do with politics,” Dr. Slaoui replied, and said those involved were running as hard as you could imagine because many other people were dying of coronavirus every day.”Many of us might, or possibly wouldn’t help this administration.It’s frankly irrelevant.”
Although he expressed doubts that a vaccine would be in good condition until the end of October, Dr. Slaoui said, he firmly believed “that we will have a vaccine before the end of the year and that it will be available in quantities that allow to vaccinate patients, subjects of maximum risk, including the elderly and those in positions with greater exposure to the virus.
He estimated that there would be enough vaccines until the end of the year to vaccinate “probably between 20 and 25 million people.”Manufacturing would be accelerated so that there would be enough doses to immunize the American population “until mid-2021.”he said.
The German fitness government plans to shorten quarantine periods for those who have been in contact with patients who tested positive for Covid-19 or those returning from high-risk countries from five to 14 days today.
“I think it makes a lot of sense to restrict the era of quarantine to five days,” Die Welt Karl Lauterbach, a member of the Social Democrats, the coalition’s younger partners in Chancellor Angela Merkel’s government, told the newspaper.
“We know that the vast majority of other people are no longer contagious five days after the onset of symptoms,” tests still show a positive result,” said Lauterbach, who is also a doctor.
Mr. Lauterbach responded to a suggestion through Christian Drosten, the country’s most influential virologist, that a shorter quarantine may be more effective than a two-week era because more people would stick to it.
Last August, Merkel rebuked tourists returning from high-risk spaces for not complying with quarantine regulations and announced more difficult fines and controls. During this period, returning tourists accounted for 40% of new infections, an amount that has declined in recent weeks., with the maximum number of Germans returning to work.
The German government recorded 1,311 new infections in 24 hours on Tuesday.There have been 246,948 cases in Germany and 9,310 deaths, according to a New York Times database.
The government officially has the Ministry of Health and the German edition of the Centers for Disease Control and Prevention in the United States to assess the protection and feasibility of such a measure, a spokesman said.
Employers continued to take off last month, but at a much slower rate than in the spring, and millions of Americans are still out of work.
The U.S. economy added 1.4 million jobs in August, labor department reported Friday, up from July 1.7 million and drastically since June 4.8 million.
The unemployment rate fell to 8.4%, up from 14.7% in April.
“We still have a long way to go,” said Beth Ann Bovino, America’s leading economist for S
Friday’s report provides some of the first transparent insights into the state of the economy as federal emergency benefits decline, adding a $ 600 weekly supplement to unemployment benefits that helped keep many families afloat in the beginning. of the pandemic. Economists warn that without the supplement, which expired at the end of July, millions of families will have a hard time paying rent and buying food, keeping the economy in check.
But because August’s employment knowledge was collected before this month, it may not reflect the full effect of loss of profits, economists warn.
For more than two decades, millions of young people in Latin America have the first in their families to move to college, a historic expansion that promised to push a generation into the professional classroom and remodel the region.
But as the pandemic takes over the region, killing thousands of people and ravaging economies, an alarming change is taking place: millions of academics are leaving their studies, according to the Inter-American Development Bank.
For example, registrations are expected to fall to 25, consisting of a penny in Colombia until the end of the year, with expected figures in other countries.
The exodus threatens decades of achievement that have helped entire communities out of poverty.
Since the early 2000s, massive investments in primary and secondary school processing plans, and the resolve to build new universities, have allowed higher education enrollments in Latin America to have more than doubled, according to the World Bank.
As the fitness crisis worsened, the New York Times spent weeks talking to students, parents, professors, universities and rectors across Colombia.
In the midst of closures, youth unemployment has soared and many academics cannot afford tuition, which even in public schools can charge between one and eight times the monthly minimum wage.
Most courses have been transferred online, but millions of people don’t have the Internet, not even a reliable cell phone connection.
Some academics said they were hungry to pay for the data, while others hid on the stairs to borrow Wi-Fi from neighbors.
At the National University, a prestigious public university in the capital, Bogota, several academics went on hunger strike on August 10, camping in a dozen tents on the empty campus in a different way, asking the government to cover their tuition fees while families were banging.
“I see no other way to pay for the semester,” said Gabriela Delgado, 22, a music student and hunger striker.
For weeks, he slept in a tent between the buildings of economy and humanities, moving on to medical checks.When he had energy, he pulled out his cello to play Bach Fragments for the other protesters.
The strike ended on August 28, responding to their demands.
Advertisement